Administrative Documents Checklist for Medical Device Registration in Egypt

1. Key takeaways

Three hard requirements govern the administrative-document portion of an Egyptian registration dossier. The first is the power of attorney: it must be an original, approved by the chairman of the board of directors, and the signature of the person responsible for liaising with the device registration department and collecting the registration licence must be certified by a bank. The second is the vigilance commitment letter: it must be issued in accordance with the circulars issued by the General Manager of the Egyptian Pharmacovigilance Center and approved by the head of the competent authority on April 24, 2018 and August 8, 2019, not as a self-drafted text. The third is the entity qualification documents: the company route requires a legalized registration authorization letter, an updated commercial register and importer licence, and a legalized distribution or agency contract; the scientific office route requires the scientific office licence and two legalized relationship letters. None of the three can be patched after submission without restarting the administrative review.

2. Legal basis

3. Expert insights

Insight 1: the bank-certified signature is a distinctly Egyptian formal gate, and it repeats across several stages of the process.

Annex 1, item 2 requires that the power of attorney be an original approved by the chairman of the board of directors, with the signature of the person in charge of liaising with the device registration department and collecting the registration licence subject to bank certification. Section 11.10 elevates this into a general rule: the registration department must be approached by a company representative formally delegated under a bank-certified (valid) power of attorney. The identical requirement reappears at the import-approval stage (GL.CAMD.007, Section 8.1.1, item 1). The practical consequence: appoint one single bank-certified representative to cover both registration and import, since every additional representative means another certification, another fee, and another document that can go stale before review.

Insight 2: the vigilance commitment letter has a defined circular basis and defined dates; it is not a free-form text.

The wording of Annex 1, item 3 is a declaration of compliance with safety procedures issued in accordance with the circulars issued by the General Manager of the Egyptian Pharmacovigilance Center and approved by the head of the competent authority on April 24, 2018 and August 8, 2019. The two dates mean the circulars were updated twice; the commitment letter must match the current version of the circular text. Using an outdated template produces a formal correction request and a full resubmission cycle, so compare the letter word for word against the latest circular before filing.

Insight 3: the company-route authorization chain runs in three segments — legal manufacturer to parent company to authorized party — and a missing segment must be repaired with relationship letters.

Annex 1, item 4 allows the registration authorization letter to be issued by the legal manufacturer, by a party legally authorized by the legal manufacturer, or by the parent company or a party legally authorized by it. The relationship letters must state the parent company, the legal manufacturer and the party responsible for issuing the registration authorization, and must clarify the names and addresses of all parties. The design prevents a broken authorization chain — the recurring problem among Chinese manufacturers is precisely that only a manufacturer authorization is provided, while the parent-company relationship is never explained.

Insight 4: the scientific office route carries two additional layers of documentation compared with the company route.

A scientific office must submit its scientific office licence; and if the manufacturing company of the devices to be registered is not a branch of the scientific office’s parent company, it must additionally provide a legalized authorization letter issued by the legal manufacturer together with a legalized no-objection letter issued by the parent company, stating that the parent company does not object to the device-owning company entrusting registration in Egypt to that scientific office. Registering third-party products through a scientific office therefore requires the parent company’s release.

Insight 5: the importer licence can be paired with a relationship letter as an alternative path.

Annex 1 offers a two-option structure: an updated commercial register plus an importer licence of the registration applicant; or an importer licence carrying the name of the manufacturer or the distribution company, accompanied by a relationship letter between the manufacturer and the supplier. This gives entities that have not yet obtained their own importer licence a workable alternative.

Insight 6: legalization of quality certificates can be waived, but the waiver is conditional.

Annex 1 states that quality certificates (USFDA CFG, CE, ISO 13485:2016, EN ISO 13485:2016 FRRESALE) issued by a reference country authority and whose authenticity the competent authority has verified with the issuing body are exempt from legalization by the chamber of commerce and the Egyptian embassy in the country of origin. If the issuing body does not confirm the validity of the certificate, legalization is required; and if the body does not reply within 3 months from the date the dossier is received, the dossier will be archived and must be re-submitted with legalization per the list published at resubmission. The waiver directly affects project timelines.

Insight 7: verification of the USFDA CFG has a designated online channel.

The annex note states that where the device data can be verified through the FDA CDRH export certificate validation system, the CFG does not require chamber-of-commerce and embassy legalization — for Class II devices, verification must also pass through the 510(k) premarket notification, and for Class III devices through PMA premarket approval.

4. Practical recommendations

1. Appoint one single bank-certified representative covering registration and import approval.
2. Execute the power of attorney as an original approved by the chairman of the board of directors: scans and unapproved versions are not accepted.
3. Use the current template for the vigilance commitment letter and verify it against the April 24, 2018 and August 8, 2019 circular versions.
4. Complete the authorization chain in one pass: provide the relationship letters together, stating all names and addresses.
5. Obtain the parent company no-objection letter before any scientific office registration of third-party products.
6. Weigh the legalization waiver for quality certificates: a 3-month silence from the issuing body archives the dossier.
7. Prepare FDA CDRH validation printouts: 510(k) verification for Class II, PMA for Class III.

5. Verification checklist

• □ Power of attorney is an original, approved by the chairman of the board of directors, with the signature certified by a bank
• □ Vigilance commitment letter checked against the 2018-04-24 and 2019-08-08 circular versions
• □ Commercial register updated and importer licence valid
• □ Distribution or agency contract legalized and valid
• □ Manufacturer-supplier relationship letter legalized, authorizing appointment of external agents
• □ Scientific office route: licence, manufacturer authorization and parent company no-objection letters ready
• □ Legalization waiver for quality certificates assessed (reference country / 3-month response window)

Regulatory information verified as of October 29, 2026, per the current text of Annex 1 and Section 11.10 of EDREX: GL.CAMD.002 Version 2.

• Local resources in Egypt: GRZAN supports manufacturers from the Chinese mainland and overseas in dealing with the Egyptian Drug Authority (EDA) on medical device registration, import approval and change applications, including registration applicant scheme design (import company / local factory / scientific office), scientific committee evaluation preparation, reference-country free sale certificate route argumentation, Arabic labelling and IFU localization, and vigilance system and periodic reporting set-up.
• Service capabilities: product attribute and risk classification (device Class I–III / IVD Class A–D), registration and re-registration, system and bundled registration applicability, three-category change determination, import approval and the annual import plan, vigilance reports and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.